The Hon Karen Andrews MP, Assistant Minister for Science

Assistant Minister for Science
The Hon Karen Andrews MP
Home » Andrews » Media Releases » Australian innovation helping to produce life-saving vaccine

Australian innovation helping to produce life-saving vaccine

16 December 2015

Joint media release with The Hon Alan Tudge MP, Assistant Minister to the Prime Minister and Assistant Minister for Social Services.

The Assistant Minister for Science, Karen Andrews, has opened a new facility at Boronia in Victoria that uses ground-breaking technology to produce vaccines that could save the lives of thousands of children around the world.

In partnership with the Institute of Pharmaceutical Sciences at Monash University and vaccine experts in Belgium, GlaxoSmithKline is using new manufacturing technology to commercially deliver vaccines.

“The efforts of everyone involved in this project will enable children living in developing countries to receive a desperately-needed vaccines,” Mrs Andrews said.

“Vaccination is one of the greatest medical achievements in human history and I know of no more worthwhile application of Australian know‑how, ingenuity and business acumen.”

The Government provided a $1 million grant to GlaxoSmithKline to help build the vaccine facility, complementing the company’s own investment of $7.7 million.

The Federal Member for Aston, Alan Tudge, said the expansion of the facility will create local jobs and help fuel the economic growth of the region.

“This new facility is great news for manufacturing in Boronia,” said Mr Tudge.

“Boronia is home to a world-leading pharmaceutical manufacturer and this new facility cements the place of GSK as an important local manufacturing employer.

“There are over 10,000 people employed in manufacturing in Knox, so investments such as these help secure manufacturing for the future.”

The National Innovation and Science Agenda, launched by the Government last week, includes initiatives to promote collaboration between industry and the research sector, including a $250 million Biomedical Translation Fund to  increase the capital available for commercialising medical research.

Media contact: Mrs Andrews’ Office: 02 6277 4360